{"ticker": {"uuid": "94d1e308-4899-4603-bc87-f8248b204aa5", "symbol": "GOSS", "name": "Gossamer Bio Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B", "summary": "Gossamer Bio (NASDAQ: GOSS) stockholders have approved a major increase in authorized common stock from 700 million to 4 billion shares. This decision, made at a special meeting on July 14, 2026, supports potential future share issuances related to new convertible notes, purchase", "url": "https://www.stocktitan.net/sec-filings/GOSS/8-k-gossamer-bio-inc-reports-material-event-6d6cef6a07ef.html", "source_name": "Stock Titan", "published_at": "2026-07-15T10:12:19", "published_display": "15 Jul 2026 10:12", "sentiment": "negative", "sentiment_pct": 40, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Gossamer Bio Stock Plummeted 82% Today \u2014 What\u2019s Behind The Crash?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQbEpjLXJEYW04TnpNZGNlTjVHOFp3N0xVSi0td0g1YzliU2NHUUJuTHBlWThaRU8yOC0wTkNFZWhpTFJPZXBWVXFIV2VwazNOcGlINm1qcUpfc2RGZUl6SFlUdHA4VXF3Q2NnRkVTRXNkSEE3R3BHb3VaN2JFSndySVhxbER5ZURaUVN2R1Q1alcyZGRQMlJiTlRnYjNYeHFnQ3pHb1lyRHhvRUU5cDVab2xFWVBnazVxYW5YbUp2TXM?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T20:30:14+00:00", "published_display": "13 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of Gossamer Bio, Inc. \u2013 MUN:4GB", "summary": "This article provides financial information for Gossamer Bio, Inc. (MUN:4GB), specifically focusing on its forward Price to Earnings (P/E) ratio. It indicates that the market was closed with no trades at the time of publication. The content appears to be a financial data page fro", "url": "https://www.tradingview.com/symbols/MUN-4GB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T13:09:46", "published_display": "13 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) Proxy filing Summary", "summary": "Gossamer Bio (GOSS) has released a proxy filing summary detailing its upcoming annual meeting scheduled for June 4, 2026. Shareholders will vote on the election of two Class II directors, the ratification of Ernst & Young LLP as the independent auditor, and an advisory vote on ex", "url": "https://quartr.com/events/gossamer-bio-inc-goss-proxy-filing_FsT6jdlY", "source_name": "Quartr", "published_at": "2026-07-11T07:10:07", "published_display": "11 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) Income Statement & Earnings", "summary": "This article provides details on Gossamer Bio's income statement and earnings. As of the time of publication, specific financial figures and comprehensive analysis are not yet available, but the article focuses on key aspects of the company's financial performance.", "url": "https://www.moomoo.com/stock/GOSS-US/financials-income-statement?chain_id=Name1K9-3FXPhg.1l2mj00&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2FNMG-US%22%7D", "source_name": "Moomoo", "published_at": "2026-07-09T15:40:44", "published_display": "09 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Shareholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Gossamer Bio, Inc. (GOSS) for potential corporate wrongdoing. The firm is encouraging shareholders who purchased Gossamer securities before June 16, 2025, and still hold them, to learn more about the investigat", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1174509", "source_name": "ACCESS Newswire", "published_at": "2026-07-09T11:00:00", "published_display": "09 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) Q1 2025 earnings summary", "summary": "Gossamer Bio (GOSS) reported its Q1 2025 earnings, highlighting the near completion of new patient screening for its pivotal phase III PROSERA study in PAH, with topline results expected in February 2026. The company ended Q1 2025 with $257.9 million in cash, providing a runway i", "url": "https://quartr.com/events/gossamer-bio-inc-goss-q1-2025_FsT6zHMu", "source_name": "Quartr", "published_at": "2026-07-09T04:10:58", "published_display": "09 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Announces Exchange Offer and Consent Solicitation for Convertible Senior Notes", "summary": "Gossamer Bio, Inc., a biopharmaceutical company specializing in treatments for pulmonary hypertension, has successfully completed an exchange offer and consent solicitation for its convertible senior notes. The transaction was advised by DLA Piper, with Cantor Fitzgerald & Co. al", "url": "https://globallegalchronicle.com/post-236673/", "source_name": "Global Legal Chronicle", "published_at": "2026-07-07T23:40:12", "published_display": "07 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GOSS - Gossamer Bio Inc Dividends", "summary": "This article provides detailed financial data and performance metrics for Gossamer Bio Inc. (NASDAQ: GOSS), including its last close price, market capitalization, income, sales, and various analyst estimates. The company's stock experienced a 2.41% decrease and shows significant ", "url": "https://finviz.com/stock?t=GOSS&p=m&b=1&r=max&ty=dv", "source_name": "Finviz", "published_at": "2026-07-07T15:13:14", "published_display": "07 Jul 2026 15:13", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio focuses on respiratory pipeline as markets weigh biotech valuations", "summary": "Gossamer Bio Inc. is a biopharmaceutical company that focuses on developing treatments for respiratory and immunological conditions. The company's strategy involves advancing drug candidates through clinical trials, with investors closely watching key data readouts and regulatory", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/gossamer-bio-focuses-on-respiratory-pipeline-as-markets-weigh-biotech/69714223", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T12:13:14", "published_display": "07 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential corporate wrongdoing by Gossamer Bio, Inc. (NASDAQ:GOSS) and its officers/directors. Investors who purchased Gossamer securities before June 16, 2025, and still hold them, are encouraged to contact the firm to assist w", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/gossamer-bio-inc.-goss-investigation-bronstein-gewirtz-and-gross-1174508", "source_name": "ACCESS Newswire", "published_at": "2026-07-07T11:00:00", "published_display": "07 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Gossamer Bio, Inc. \u2013 DUS:4GB", "summary": "This article presents the price to earnings forward data for Gossamer Bio, Inc. (DUS:4GB). It highlights the current period value and change, based on data provided by various financial services. The piece is primarily a data presentation from TradingView.", "url": "https://www.tradingview.com/symbols/DUS-4GB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T02:00:25", "published_display": "06 Jul 2026 02:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Shareholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gossamer Bio, Inc. (NASDAQ:GOSS) securities who bought prior to June 16, 2025, and still hold them. The investigation aims to determine if Gossamer's officers and/or directors engaged ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-gossamer-bio-inc.-1174507", "source_name": "ACCESS Newswire", "published_at": "2026-07-05T11:00:00", "published_display": "05 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) Stock Fair Value Moves Lower After Mixed Analyst Target Changes", "summary": "Gossamer Bio's fair value estimate has been reduced from $4.46 to $3.86 due to mixed analyst commentary, despite some firms maintaining a \"Buy\" rating. While H.C. Wainwright sees upside post-dilution and balance sheet cleanup, Goldman Sachs suspended its rating due to going conce", "url": "https://finance.yahoo.com/markets/stocks/articles/gossamer-bio-goss-stock-fair-140823165.html", "source_name": "Market source", "published_at": "2026-07-02T14:13:06", "published_display": "02 Jul 2026 14:13", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Gossamer Bio For: 1 July By Investing.com", "summary": "This article from Investing.com announces the filing of Form 13D/A for Gossamer Bio on July 1. It is a brief news item indicating a regulatory filing has occurred for the company GOSS, which saw a 1.82% increase.", "url": "https://ca.investing.com/news/stock-market-news/form-13da-gossamer-bio-for-1-july-93CH-4717475", "source_name": "Investing.com Canada", "published_at": "2026-07-02T02:13:20", "published_display": "02 Jul 2026 02:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "D.E. Shaw discloses 8.3% Gossamer Bio (GOSS) ownership stake", "summary": "D.E. Shaw-affiliated entities have reported an 8.3% beneficial ownership stake in Gossamer Bio, Inc. (GOSS) common stock, totaling 40,630,726 shares out of 488,846,722 outstanding as of June 5, 2026. This ownership is distributed among Valence (7.8%), Cogence (0.4%), and funds ma", "url": "https://www.stocktitan.net/sec-filings/GOSS/schedule-13d-a-gossamer-bio-inc-amended-major-shareholder-report-190a35714168.html", "source_name": "Stock Titan", "published_at": "2026-07-02T02:13:19", "published_display": "02 Jul 2026 02:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio sets conversion rate for 2030 convertible notes", "summary": "Gossamer Bio (NASDAQ:GOSS) has announced the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030, set at 5,347.5936 shares of common stock per $1,000 principal amount. The biopharmaceutical company also established an initial exercise price ", "url": "https://www.investing.com/news/company-news/gossamer-bio-sets-conversion-rate-for-2030-convertible-notes-93CH-4770613", "source_name": "Investing.com", "published_at": "2026-07-02T01:13:06", "published_display": "02 Jul 2026 01:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gossamer-bio-inc-announces-determination-130000442.html", "source_name": "Business Wire", "published_at": "2026-07-01T13:00:00+00:00", "published_display": "01 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio fixes note conversion at $0.19, warrants at $0.34", "summary": "Gossamer Bio (NASDAQ: GOSS) has set the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 at 5,347.5936 shares per $1,000 principal amount, resulting in a conversion price of approximately $0.19 per share. Additionally, the initial exercis", "url": "https://www.stocktitan.net/news/GOSS/gossamer-bio-inc-announces-determination-of-conversion-rate-for-7-50-d5vjc69dd41a.html", "source_name": "Stock Titan", "published_at": "2026-07-01T13:39:44", "published_display": "01 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (NASDAQ: GOSS) sets note conversion rate and warrant exercise price", "summary": "Gossamer Bio (NASDAQ: GOSS) has announced the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 and the exercise price for its Purchase Warrants. Each $1,000 principal amount of notes will convert into 5,347.5936 shares of common stock, im", "url": "https://www.stocktitan.net/sec-filings/GOSS/8-k-gossamer-bio-inc-reports-material-event-a0af36f83ec6.html", "source_name": "Stock Titan", "published_at": "2026-07-01T13:08:50", "published_display": "01 Jul 2026 13:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Gossamer Bio, Inc. \u2013 NASDAQ:GOSS", "summary": "This article provides a financial data point for Gossamer Bio, Inc. (NASDAQ: GOSS), specifically its forward price-to-sales ratio. The content appears to be a stub or a section from a larger financial data platform, indicating the period, value, and change for this metric.", "url": "https://www.tradingview.com/symbols/NASDAQ-GOSS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T00:39:16", "published_display": "30 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Gossamer Bio, Inc. \u2013 NASDAQ:GOSS", "summary": "The article focuses on the \"Price to book forward\" financial metric for Gossamer Bio, Inc. (NASDAQ: GOSS). It provides access to this specific financial data for the company, indicating that additional historical values, percentage changes, and comparison periods are available on", "url": "https://www.tradingview.com/symbols/NASDAQ-GOSS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:10:52", "published_display": "29 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts Gossamer Bio stock price target to $2 on debt exchange By Investing.com", "summary": "H.C. Wainwright has reduced its price target for Gossamer Bio Inc. (NASDAQ:GOSS) from $5 to $2, while maintaining a Buy rating, citing the company's recent convertible note exchange offer as the primary reason. Gossamer Bio's management anticipates submitting a New Drug Applicati", "url": "https://m.au.investing.com/news/stock-market-news/hc-wainwright-cuts-gossamer-bio-stock-price-target-to-2-on-debt-exchange-93CH-4506503?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-27T02:39:54", "published_display": "27 Jun 2026 02:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts Gossamer Bio stock price target to $2 on debt exchange", "summary": "H.C. Wainwright reduced its price target for Gossamer Bio Inc. (NASDAQ:GOSS) to $2 from $5, while maintaining a Buy rating, citing the company's recent convertible note exchange offer and consent solicitation as the primary reason. This debt restructuring aims to fully fund opera", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-cuts-gossamer-bio-stock-price-target-to-2-on-debt-exchange-93CH-4762543", "source_name": "Investing.com", "published_at": "2026-06-26T23:40:12", "published_display": "26 Jun 2026 23:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. Actuals & Estimates (NASDAQ:GOSS)", "summary": "This article provides current financial actuals and analyst estimates for Gossamer Bio, Inc. (NASDAQ:GOSS), including its stock price, market capitalization, volatility, and upcoming earnings dates. It highlights recent stock performance, revenue, net income, and offers a summary", "url": "https://www.tradingview.com/symbols/NASDAQ-GOSS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T22:38:58", "published_display": "25 Jun 2026 22:38", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Gossamer Bio, Inc. (GOSS) for potential corporate wrongdoing. The firm is encouraging shareholders who purchased Gossamer securities before June 16, 2025, and still hold them, to contact them to assist with the", "url": "https://natlawreview.com/press-releases/gossamer-bio-inc-goss-investigation-bronstein-gewirtz-grossman-llc-0", "source_name": "The National Law Review", "published_at": "2026-06-25T15:10:32", "published_display": "25 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (NasdaqGS:GOSS) Stock Forecast & Analyst Predictions", "summary": "Gossamer Bio (GOSS) is projected to grow earnings and revenue significantly, with analysts forecasting profitability by 2028. However, the company faces major risks including shareholder dilution, negative equity, high stock volatility, and Nasdaq's minimum bid price requirement.", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-goss/gossamer-bio/future", "source_name": "Simply Wall Street", "published_at": "2026-06-25T11:39:21", "published_display": "25 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Gossamer Bio Inc (GOSS) has an earnings forecast score of 6.50, ranking 327 out of 388 in the Biotechnology & Medical Research industry, with an average analyst price target of $9.00. Analysts' consensus based on 8 ratings is \"Hold\" for GOSS stock, with an anticipated revenue of ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-goss/earnings", "source_name": "TradingKey", "published_at": "2026-06-23T22:10:32", "published_display": "23 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Gossamer Bio, Inc. (GOSS) on behalf of investors who purchased securities prior to June 16, 2025, and continue to hold them. The investigation focuses on potential corporate wrongdoing by the company's o", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-gossamer-bio-1174502", "source_name": "ACCESS Newswire", "published_at": "2026-06-23T11:00:00", "published_display": "23 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) Stock Faces Mixed Analyst Target Changes On Funding Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOM2V0ZVZzRGZKVjI3eTJEb0g5MjctSU03N19RaTdpVlNXdm42akRoQXBNS2QwOEpjQTFycEx6VkFFUkl5VWwzZWdzckdYSnNMdTdJTTJVYWVWaGtqdWlIUS1XcXVnSF81enA0TDdrMTZvaUFabEFjdDAyVHdvNDI3bVdMMGdkd21IX3hCYmhlX0dQaVZuS2xUU3Vn?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Insiders Are Down US$45k But Regain Some Losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strategic Debt Reduction and ...", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/gossamer-bio-inc-goss-q1-221915866.html", "source_name": "GuruFocus.com", "published_at": "2026-06-17T22:19:15+00:00", "published_display": "17 Jun 2026 22:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gossamer-bio-inc-announces-final-120000469.html", "source_name": "Business Wire", "published_at": "2026-06-17T12:00:00+00:00", "published_display": "17 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors swap $181M of Gossamer 2027 debt for new notes, stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNblN6VUloWnJ2eERNR1JabjdNblJKTjhoOHYyOGhlZGZZRF8tcTBPTWd4SnE0YzBMVTZReXdKMmM4Z1RCMkhUR25rVW12Ykk2SUppNFNOTXZWUGNjODRvRlpaTUdkR1RFRjUwcWtYYzVsYjFzLTJjaFZXU3lTdHlTa0M3WDNpUXVfa2o2ZnV3eWVvTGdPNVVKMGV6MmIwX1FPRExSN0lyb3lpa3ROdnFkSUxjR2FUajIzZHZXdzNB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13G] Gossamer Bio, Inc. Passive Investment Disclosure (>5%)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPOHh3Z3pITGp1b0RhVHhtdHRPRzZuSnV2MDhWaVpWWTBXNkpwWW9DZ1lwVGJtWkhOb2FkRTdIdS1IeU1Jd0dBMExBLUhfNVg4bG13SnJsNnpOT1FHZ3BGQkhLNjZnbThtV0J2U3ZKMWVDNGNrQWNUZDZ2dk9IWkVrZ2s4cUo0NExndXdmS3dCUzhJM1J4OWtZZFZVMTRpNkpYdDd4WkdIejU5TVVESFkxQ180N0VlVDJUaENQTHdNRnI?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) holders re-elect directors and approve say-on-pay", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZVBaSlkxdjk2d2o1NHdwSDZVTzRCbmdqZWw5ajF5UGRaR1VaMm44Q194QmhPRlFjMy0yUXJKTVRaX0lsYU9VR2xLc21zbll2V3ZRbUNhM18wMGVSXzVraFNyT0pVMHNJYlpKSzJrT3JNMlFRWnJTazg1T0E1WmxrR2xBY25BRVl3REtlSm9HNkxXbHJLYkJvS2RwZFNvMi1jQ1Z5TGFtOFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Reports Early Tender Results for Exchange Offer", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gossamer-bio-reports-early-tender-130329830.html", "source_name": "MT Newswires", "published_at": "2026-06-03T13:03:29+00:00", "published_display": "03 Jun 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gossamer-bio-inc-announces-early-120000122.html", "source_name": "Business Wire", "published_at": "2026-06-03T12:00:00+00:00", "published_display": "03 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Investment Story For Gossamer Bio (GOSS) Is Quietly Shifting Without New Analyst Signals", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/investment-story-gossamer-bio-goss-100750544.html", "source_name": "Simply Wall St.", "published_at": "2026-06-03T10:07:50+00:00", "published_display": "03 Jun 2026 10:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Extends Early Tender Deadline for Exchange of Convertible Notes due 2027", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gossamer-bio-extends-early-tender-131143776.html", "source_name": "MT Newswires", "published_at": "2026-06-02T13:11:43+00:00", "published_display": "02 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure\u2013 HBSS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxQLXU4LVZHQWdtS256LW9zMmxPTk12bGVrWW1IdDE3YUhfcmJmYkNTN09tcTYxT2xHdmM3WW9Id3RuX19Hd19sNHJ2bmMwWjNhRzlUUjdFWTNNZW9Db2tIVTEtSjhwRk9JaDhiY044cUJsdFZsSC1tbEZpbGIzMzRtR05Kdm51bzZ4US01LWo2OUFfVlZDSlpuS2lZZnJ4N01jVm11Z1BPdEpqOV9iTTNvZzhfTlFqcFpESzNJLW9LTkNqMXd6VExPZWtRTWRrZW5odFVLcVNhMUl1WTBQenNQUndZNU54MEFVT3dpSmFzX1FtM1dtUU9rY1ZKajVweWhBSDdfeUtZWkNnUQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNVzRBeWF4MDlOTjRpN3laTEFXMEROLTFQNE5aa2ZtUUtsQXFBZVpjU2I3VlRCN1IyMW9lUGJ6TXhEMVh2MDNzaUtmbTdzVHl1RkNzSHJkUHljQWRRT1pwZVB3bG10bU03Y1lFaTlyenhrY1loM2h3VHFfZ1F3QUVIVjNoMk5tQUhUZmVMQTU0MU1OMHZSVkdYS0ZYSWN0OEZUM0JCTA?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonary hypertension drug developer Gossamer Bio sets May 18 Q1 update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdWVBZjBGOXRPQ1RsWHlZSTc2M2E2U1JXd0NpdHRHbDhibHZyNU04WklrZ3QtRkVFbUM5amoxUVkzZi1MNXZ0ZGJDeFFBQkJhYkJocVFITUw0VV9BRkJaZElWTlZ5Szg2eDVIRUV3aXMxZVFUNWtxb2drNkVtQUxCUmlzb2lPbDZjemNtZGhuQ2xTQTZNOVJXYzBxMFdDOWRZYU9MNjdTbmNwbHpPOWtBU093LXBwek5tT2h4TA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The Gossamer Bio (GOSS) Story Is Shifting After The PROSERA Miss And Cash Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxON21NUExmYVZHUVMwRWg4RHd2SEc3UXFnVDFIa3NzRDJRQzBfTkVYdlRSZV9YWFdkam42dWtKbVloS2hBTzhwSFVUMHRyM0FmSWlmd0JiaTF2NWNHVkg4Q19vdEVoRDkzbkVMaDEtRE5CTGZrc0RjRG5wNnp5dHhMYXBGWGUxR1hRQ0xVMUViSmU1cjFvaElmeDNpREJka3VZUVNR?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 Setback", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQdzRGVE9mZl93aDhHOXlpbURfS01KUWRpZTd4ZVZxOEQzaXlUVzBNZGIxWlRhZ0V6OVp0UXlfTGpZTXFQc3pva2tpeE5nZHhBclJNMHVTLTVhTTJHYzhsaDRvTDJ2RENlNWo1ZXVhYkpYMUc2Smpsd3FDQVBjUjRGTTlEWHFvZlJuUzlRMmg5UHJ0bzUxR0tPQUo3RklkTUJEVnk0?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Bullish Analysts Still See Major Upside in Gossamer Bio (GOSS) After PROSERA Setback", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPaDA5R0h1cDljZ0lYY2cwZVE3M0RNVk1xUDZzZEE2QmVoc3lZb0t3a0N0OTcyZnNzRXAxam9ZWXUxYlE4YzNENndMOVhPS08zQllBeTlWZFl5VEVNd3VuTjFad3pYOXlxMURtTVdSVTl4TkJkazYxU05zUGJzc21rV0M0T2F6cDloOExpWXB1Rlc2ZGNGUUUwMG5PUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Gossamer Bio (GOSS) Continues Downtrend Despite Impressive Revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOQUtyZFdiZ3pXRVRReFFFSWNlcVFZZnQ3YlRMdWw4dVVfX1pQNzVIRDJDUVdLRkhwM3hQSHRVaWFUTWxDYXMtbGtxanQ1eDh2M3hTUG5jRHRHaDZJNVFMUm02UUdOY2NVajJUbURqRGtCcGN2NnBQOUdVcFdIVHFPNHhOaXVyWGhkZmRJekhCenBwRy1iRU05ZDVreXU0TE5PXzRmTkdUUHA0UQ?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) Quarterly Loss Deepens To US$47 Million Testing Bullish Profitability Narrative", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNRXIxUnVPSEdGc2ZkZ0xPTV9LVll4a0lGVTRFeUZCWHE3Z0N0RkQ1SEZGbzQySkFVZV9hbFo2X0RPUWlmWTlKaTBXTWI3SE5XcjVpMmdrT1pfTWZsZy1aY21HeWtnX2NxMDBtZTNfbUtTX3VoS01NNzJUNFV3OUJReTFKLUI5UGpfZnBzZ1BaTFphQUVPTnVvNEVtSjE5TVVfN3pSVFltZ19NTGZmRWZWQXdpMGtMT19XX0REMzJwaVJBTkdJS1BnUTVpTXlCSlVKWHpCdWNiOTk5SmJWblRr0gHkAUFVX3lxTE1UWFlpN0l2NXJEQXJHWlliNVJZR25BWW1KdmY3MUVmUkl1NHFoUXNycmxWX09EWW13ekpGcVM4UlpMbDdnN0NCQUVyYlAwWmtmOEdMbFNXY3Y5VnRhcVpoVUVKSDVkUUZUdERGZ1FEc05qRGx3Z3VnSzJXVVFDeldGRkREdjFkVjlCR09yODRwYlVJVHhLUUhoazYwZjBuY2RWSWFlalQ3ZmZIRC1nY080cmtoWFhGdTZDam9NUHhQS3pORVRlNl9wSjJKM2F6VGJfbzVNNXUxejFKUHhzUlNGcXIyTw?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Gossamer Bio, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNMkVkVjBLcDRYOERnTFUxX1VHa2NOVHNOcVJPV0wtUW5VV3NLV3k5dzBxeUFSSDhyRXVTb0dZZWJESjVFeUR6WEZtUHN6N3NobFkzTE5wWGpSbjRLQk82UkhieEFXUkZvbm1ITjU3RmRCeDNEMl83MEtTVGY2VV91Y3Ewb19kam1STzhKbE4xYWZxWVBZTFU2Q2c2dGQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street Valuations", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOMDh4bUhHX0ZnZlNVUUlTSXNTRFhzYTdWNnJHYXRkLU9CQUhpNXE0TTRfU3Q1NFQxRVhEbnQ5aHREUnlIb1FUQi1wak9tZldibTExS1AtVmdFb1FJend0WG5hdnZiaVpqRHowdkttZVBaZ0ZnMGs2ZzVWTlVsSEVBREpsOTE?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBsQTdCS24zQ3QxdFVlSWtRcGpjb0Nra1RfWFVoTFNEQ0g4cC1kU0hTSFZURTA4VjlLNGhrR19FVUdaTDBCZnktUWxBSXRiYVZWWkNveE52THV1OVdYSlJaTFdqeWw2SzFvRW96Sk1YckRHRVhRZVQyd2VOZjJ2dw?oc=5", "source_name": "Market source", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B", "summary": "Gossamer Bio (NASDAQ: GOSS) stockholders have approved a major increase in authorized common stock from 700 million to 4 billion shares. This decision, made at a special meeting on July 14, 2026, supports potential future share issuances related to new convertible notes, purchase", "url": "https://www.stocktitan.net/sec-filings/GOSS/8-k-gossamer-bio-inc-reports-material-event-6d6cef6a07ef.html", "source_name": "Stock Titan", "published_at": "2026-07-15T10:12:19", "published_display": "15 Jul 2026 10:12", "sentiment": "negative", "sentiment_pct": 40, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Stock Plummeted 82% Today \u2014 What\u2019s Behind The Crash?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQbEpjLXJEYW04TnpNZGNlTjVHOFp3N0xVSi0td0g1YzliU2NHUUJuTHBlWThaRU8yOC0wTkNFZWhpTFJPZXBWVXFIV2VwazNOcGlINm1qcUpfc2RGZUl6SFlUdHA4VXF3Q2NnRkVTRXNkSEE3R3BHb3VaN2JFSndySVhxbER5ZURaUVN2R1Q1alcyZGRQMlJiTlRnYjNYeHFnQ3pHb1lyRHhvRUU5cDVab2xFWVBnazVxYW5YbUp2TXM?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T20:30:14+00:00", "published_display": "13 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Gossamer Bio, Inc. \u2013 MUN:4GB", "summary": "This article provides financial information for Gossamer Bio, Inc. (MUN:4GB), specifically focusing on its forward Price to Earnings (P/E) ratio. It indicates that the market was closed with no trades at the time of publication. The content appears to be a financial data page fro", "url": "https://www.tradingview.com/symbols/MUN-4GB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T13:09:46", "published_display": "13 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) Proxy filing Summary", "summary": "Gossamer Bio (GOSS) has released a proxy filing summary detailing its upcoming annual meeting scheduled for June 4, 2026. Shareholders will vote on the election of two Class II directors, the ratification of Ernst & Young LLP as the independent auditor, and an advisory vote on ex", "url": "https://quartr.com/events/gossamer-bio-inc-goss-proxy-filing_FsT6jdlY", "source_name": "Quartr", "published_at": "2026-07-11T07:10:07", "published_display": "11 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) Income Statement & Earnings", "summary": "This article provides details on Gossamer Bio's income statement and earnings. As of the time of publication, specific financial figures and comprehensive analysis are not yet available, but the article focuses on key aspects of the company's financial performance.", "url": "https://www.moomoo.com/stock/GOSS-US/financials-income-statement?chain_id=Name1K9-3FXPhg.1l2mj00&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2FNMG-US%22%7D", "source_name": "Moomoo", "published_at": "2026-07-09T15:40:44", "published_display": "09 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Shareholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Gossamer Bio, Inc. (GOSS) for potential corporate wrongdoing. The firm is encouraging shareholders who purchased Gossamer securities before June 16, 2025, and still hold them, to learn more about the investigat", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1174509", "source_name": "ACCESS Newswire", "published_at": "2026-07-09T11:00:00", "published_display": "09 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) Q1 2025 earnings summary", "summary": "Gossamer Bio (GOSS) reported its Q1 2025 earnings, highlighting the near completion of new patient screening for its pivotal phase III PROSERA study in PAH, with topline results expected in February 2026. The company ended Q1 2025 with $257.9 million in cash, providing a runway i", "url": "https://quartr.com/events/gossamer-bio-inc-goss-q1-2025_FsT6zHMu", "source_name": "Quartr", "published_at": "2026-07-09T04:10:58", "published_display": "09 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Announces Exchange Offer and Consent Solicitation for Convertible Senior Notes", "summary": "Gossamer Bio, Inc., a biopharmaceutical company specializing in treatments for pulmonary hypertension, has successfully completed an exchange offer and consent solicitation for its convertible senior notes. The transaction was advised by DLA Piper, with Cantor Fitzgerald & Co. al", "url": "https://globallegalchronicle.com/post-236673/", "source_name": "Global Legal Chronicle", "published_at": "2026-07-07T23:40:12", "published_display": "07 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GOSS - Gossamer Bio Inc Dividends", "summary": "This article provides detailed financial data and performance metrics for Gossamer Bio Inc. (NASDAQ: GOSS), including its last close price, market capitalization, income, sales, and various analyst estimates. The company's stock experienced a 2.41% decrease and shows significant ", "url": "https://finviz.com/stock?t=GOSS&p=m&b=1&r=max&ty=dv", "source_name": "Finviz", "published_at": "2026-07-07T15:13:14", "published_display": "07 Jul 2026 15:13", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio focuses on respiratory pipeline as markets weigh biotech valuations", "summary": "Gossamer Bio Inc. is a biopharmaceutical company that focuses on developing treatments for respiratory and immunological conditions. The company's strategy involves advancing drug candidates through clinical trials, with investors closely watching key data readouts and regulatory", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/gossamer-bio-focuses-on-respiratory-pipeline-as-markets-weigh-biotech/69714223", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T12:13:14", "published_display": "07 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential corporate wrongdoing by Gossamer Bio, Inc. (NASDAQ:GOSS) and its officers/directors. Investors who purchased Gossamer securities before June 16, 2025, and still hold them, are encouraged to contact the firm to assist w", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/gossamer-bio-inc.-goss-investigation-bronstein-gewirtz-and-gross-1174508", "source_name": "ACCESS Newswire", "published_at": "2026-07-07T11:00:00", "published_display": "07 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Gossamer Bio, Inc. \u2013 DUS:4GB", "summary": "This article presents the price to earnings forward data for Gossamer Bio, Inc. (DUS:4GB). It highlights the current period value and change, based on data provided by various financial services. The piece is primarily a data presentation from TradingView.", "url": "https://www.tradingview.com/symbols/DUS-4GB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T02:00:25", "published_display": "06 Jul 2026 02:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Shareholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gossamer Bio, Inc. (NASDAQ:GOSS) securities who bought prior to June 16, 2025, and still hold them. The investigation aims to determine if Gossamer's officers and/or directors engaged ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-gossamer-bio-inc.-1174507", "source_name": "ACCESS Newswire", "published_at": "2026-07-05T11:00:00", "published_display": "05 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) Stock Fair Value Moves Lower After Mixed Analyst Target Changes", "summary": "Gossamer Bio's fair value estimate has been reduced from $4.46 to $3.86 due to mixed analyst commentary, despite some firms maintaining a \"Buy\" rating. While H.C. Wainwright sees upside post-dilution and balance sheet cleanup, Goldman Sachs suspended its rating due to going conce", "url": "https://finance.yahoo.com/markets/stocks/articles/gossamer-bio-goss-stock-fair-140823165.html", "source_name": "Market source", "published_at": "2026-07-02T14:13:06", "published_display": "02 Jul 2026 14:13", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Gossamer Bio For: 1 July By Investing.com", "summary": "This article from Investing.com announces the filing of Form 13D/A for Gossamer Bio on July 1. It is a brief news item indicating a regulatory filing has occurred for the company GOSS, which saw a 1.82% increase.", "url": "https://ca.investing.com/news/stock-market-news/form-13da-gossamer-bio-for-1-july-93CH-4717475", "source_name": "Investing.com Canada", "published_at": "2026-07-02T02:13:20", "published_display": "02 Jul 2026 02:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "D.E. Shaw discloses 8.3% Gossamer Bio (GOSS) ownership stake", "summary": "D.E. Shaw-affiliated entities have reported an 8.3% beneficial ownership stake in Gossamer Bio, Inc. (GOSS) common stock, totaling 40,630,726 shares out of 488,846,722 outstanding as of June 5, 2026. This ownership is distributed among Valence (7.8%), Cogence (0.4%), and funds ma", "url": "https://www.stocktitan.net/sec-filings/GOSS/schedule-13d-a-gossamer-bio-inc-amended-major-shareholder-report-190a35714168.html", "source_name": "Stock Titan", "published_at": "2026-07-02T02:13:19", "published_display": "02 Jul 2026 02:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio sets conversion rate for 2030 convertible notes", "summary": "Gossamer Bio (NASDAQ:GOSS) has announced the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030, set at 5,347.5936 shares of common stock per $1,000 principal amount. The biopharmaceutical company also established an initial exercise price ", "url": "https://www.investing.com/news/company-news/gossamer-bio-sets-conversion-rate-for-2030-convertible-notes-93CH-4770613", "source_name": "Investing.com", "published_at": "2026-07-02T01:13:06", "published_display": "02 Jul 2026 01:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gossamer-bio-inc-announces-determination-130000442.html", "source_name": "Business Wire", "published_at": "2026-07-01T13:00:00+00:00", "published_display": "01 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio fixes note conversion at $0.19, warrants at $0.34", "summary": "Gossamer Bio (NASDAQ: GOSS) has set the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 at 5,347.5936 shares per $1,000 principal amount, resulting in a conversion price of approximately $0.19 per share. Additionally, the initial exercis", "url": "https://www.stocktitan.net/news/GOSS/gossamer-bio-inc-announces-determination-of-conversion-rate-for-7-50-d5vjc69dd41a.html", "source_name": "Stock Titan", "published_at": "2026-07-01T13:39:44", "published_display": "01 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (NASDAQ: GOSS) sets note conversion rate and warrant exercise price", "summary": "Gossamer Bio (NASDAQ: GOSS) has announced the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 and the exercise price for its Purchase Warrants. Each $1,000 principal amount of notes will convert into 5,347.5936 shares of common stock, im", "url": "https://www.stocktitan.net/sec-filings/GOSS/8-k-gossamer-bio-inc-reports-material-event-a0af36f83ec6.html", "source_name": "Stock Titan", "published_at": "2026-07-01T13:08:50", "published_display": "01 Jul 2026 13:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Gossamer Bio, Inc. \u2013 NASDAQ:GOSS", "summary": "This article provides a financial data point for Gossamer Bio, Inc. (NASDAQ: GOSS), specifically its forward price-to-sales ratio. The content appears to be a stub or a section from a larger financial data platform, indicating the period, value, and change for this metric.", "url": "https://www.tradingview.com/symbols/NASDAQ-GOSS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T00:39:16", "published_display": "30 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Gossamer Bio, Inc. \u2013 NASDAQ:GOSS", "summary": "The article focuses on the \"Price to book forward\" financial metric for Gossamer Bio, Inc. (NASDAQ: GOSS). It provides access to this specific financial data for the company, indicating that additional historical values, percentage changes, and comparison periods are available on", "url": "https://www.tradingview.com/symbols/NASDAQ-GOSS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:10:52", "published_display": "29 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts Gossamer Bio stock price target to $2 on debt exchange By Investing.com", "summary": "H.C. Wainwright has reduced its price target for Gossamer Bio Inc. (NASDAQ:GOSS) from $5 to $2, while maintaining a Buy rating, citing the company's recent convertible note exchange offer as the primary reason. Gossamer Bio's management anticipates submitting a New Drug Applicati", "url": "https://m.au.investing.com/news/stock-market-news/hc-wainwright-cuts-gossamer-bio-stock-price-target-to-2-on-debt-exchange-93CH-4506503?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-27T02:39:54", "published_display": "27 Jun 2026 02:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts Gossamer Bio stock price target to $2 on debt exchange", "summary": "H.C. Wainwright reduced its price target for Gossamer Bio Inc. (NASDAQ:GOSS) to $2 from $5, while maintaining a Buy rating, citing the company's recent convertible note exchange offer and consent solicitation as the primary reason. This debt restructuring aims to fully fund opera", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-cuts-gossamer-bio-stock-price-target-to-2-on-debt-exchange-93CH-4762543", "source_name": "Investing.com", "published_at": "2026-06-26T23:40:12", "published_display": "26 Jun 2026 23:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. Actuals & Estimates (NASDAQ:GOSS)", "summary": "This article provides current financial actuals and analyst estimates for Gossamer Bio, Inc. (NASDAQ:GOSS), including its stock price, market capitalization, volatility, and upcoming earnings dates. It highlights recent stock performance, revenue, net income, and offers a summary", "url": "https://www.tradingview.com/symbols/NASDAQ-GOSS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T22:38:58", "published_display": "25 Jun 2026 22:38", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Gossamer Bio, Inc. (GOSS) for potential corporate wrongdoing. The firm is encouraging shareholders who purchased Gossamer securities before June 16, 2025, and still hold them, to contact them to assist with the", "url": "https://natlawreview.com/press-releases/gossamer-bio-inc-goss-investigation-bronstein-gewirtz-grossman-llc-0", "source_name": "The National Law Review", "published_at": "2026-06-25T15:10:32", "published_display": "25 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (NasdaqGS:GOSS) Stock Forecast & Analyst Predictions", "summary": "Gossamer Bio (GOSS) is projected to grow earnings and revenue significantly, with analysts forecasting profitability by 2028. However, the company faces major risks including shareholder dilution, negative equity, high stock volatility, and Nasdaq's minimum bid price requirement.", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-goss/gossamer-bio/future", "source_name": "Simply Wall Street", "published_at": "2026-06-25T11:39:21", "published_display": "25 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Gossamer Bio Inc (GOSS) has an earnings forecast score of 6.50, ranking 327 out of 388 in the Biotechnology & Medical Research industry, with an average analyst price target of $9.00. Analysts' consensus based on 8 ratings is \"Hold\" for GOSS stock, with an anticipated revenue of ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-goss/earnings", "source_name": "TradingKey", "published_at": "2026-06-23T22:10:32", "published_display": "23 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Gossamer Bio, Inc. (GOSS) on behalf of investors who purchased securities prior to June 16, 2025, and continue to hold them. The investigation focuses on potential corporate wrongdoing by the company's o", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-gossamer-bio-1174502", "source_name": "ACCESS Newswire", "published_at": "2026-06-23T11:00:00", "published_display": "23 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) Stock Faces Mixed Analyst Target Changes On Funding Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOM2V0ZVZzRGZKVjI3eTJEb0g5MjctSU03N19RaTdpVlNXdm42akRoQXBNS2QwOEpjQTFycEx6VkFFUkl5VWwzZWdzckdYSnNMdTdJTTJVYWVWaGtqdWlIUS1XcXVnSF81enA0TDdrMTZvaUFabEFjdDAyVHdvNDI3bVdMMGdkd21IX3hCYmhlX0dQaVZuS2xUU3Vn?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Insiders Are Down US$45k But Regain Some Losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strategic Debt Reduction and ...", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/gossamer-bio-inc-goss-q1-221915866.html", "source_name": "GuruFocus.com", "published_at": "2026-06-17T22:19:15+00:00", "published_display": "17 Jun 2026 22:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gossamer-bio-inc-announces-final-120000469.html", "source_name": "Business Wire", "published_at": "2026-06-17T12:00:00+00:00", "published_display": "17 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors swap $181M of Gossamer 2027 debt for new notes, stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNblN6VUloWnJ2eERNR1JabjdNblJKTjhoOHYyOGhlZGZZRF8tcTBPTWd4SnE0YzBMVTZReXdKMmM4Z1RCMkhUR25rVW12Ykk2SUppNFNOTXZWUGNjODRvRlpaTUdkR1RFRjUwcWtYYzVsYjFzLTJjaFZXU3lTdHlTa0M3WDNpUXVfa2o2ZnV3eWVvTGdPNVVKMGV6MmIwX1FPRExSN0lyb3lpa3ROdnFkSUxjR2FUajIzZHZXdzNB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13G] Gossamer Bio, Inc. Passive Investment Disclosure (>5%)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPOHh3Z3pITGp1b0RhVHhtdHRPRzZuSnV2MDhWaVpWWTBXNkpwWW9DZ1lwVGJtWkhOb2FkRTdIdS1IeU1Jd0dBMExBLUhfNVg4bG13SnJsNnpOT1FHZ3BGQkhLNjZnbThtV0J2U3ZKMWVDNGNrQWNUZDZ2dk9IWkVrZ2s4cUo0NExndXdmS3dCUzhJM1J4OWtZZFZVMTRpNkpYdDd4WkdIejU5TVVESFkxQ180N0VlVDJUaENQTHdNRnI?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) holders re-elect directors and approve say-on-pay", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZVBaSlkxdjk2d2o1NHdwSDZVTzRCbmdqZWw5ajF5UGRaR1VaMm44Q194QmhPRlFjMy0yUXJKTVRaX0lsYU9VR2xLc21zbll2V3ZRbUNhM18wMGVSXzVraFNyT0pVMHNJYlpKSzJrT3JNMlFRWnJTazg1T0E1WmxrR2xBY25BRVl3REtlSm9HNkxXbHJLYkJvS2RwZFNvMi1jQ1Z5TGFtOFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Reports Early Tender Results for Exchange Offer", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gossamer-bio-reports-early-tender-130329830.html", "source_name": "MT Newswires", "published_at": "2026-06-03T13:03:29+00:00", "published_display": "03 Jun 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gossamer-bio-inc-announces-early-120000122.html", "source_name": "Business Wire", "published_at": "2026-06-03T12:00:00+00:00", "published_display": "03 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Investment Story For Gossamer Bio (GOSS) Is Quietly Shifting Without New Analyst Signals", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/investment-story-gossamer-bio-goss-100750544.html", "source_name": "Simply Wall St.", "published_at": "2026-06-03T10:07:50+00:00", "published_display": "03 Jun 2026 10:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Extends Early Tender Deadline for Exchange of Convertible Notes due 2027", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gossamer-bio-extends-early-tender-131143776.html", "source_name": "MT Newswires", "published_at": "2026-06-02T13:11:43+00:00", "published_display": "02 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure\u2013 HBSS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxQLXU4LVZHQWdtS256LW9zMmxPTk12bGVrWW1IdDE3YUhfcmJmYkNTN09tcTYxT2xHdmM3WW9Id3RuX19Hd19sNHJ2bmMwWjNhRzlUUjdFWTNNZW9Db2tIVTEtSjhwRk9JaDhiY044cUJsdFZsSC1tbEZpbGIzMzRtR05Kdm51bzZ4US01LWo2OUFfVlZDSlpuS2lZZnJ4N01jVm11Z1BPdEpqOV9iTTNvZzhfTlFqcFpESzNJLW9LTkNqMXd6VExPZWtRTWRrZW5odFVLcVNhMUl1WTBQenNQUndZNU54MEFVT3dpSmFzX1FtM1dtUU9rY1ZKajVweWhBSDdfeUtZWkNnUQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNVzRBeWF4MDlOTjRpN3laTEFXMEROLTFQNE5aa2ZtUUtsQXFBZVpjU2I3VlRCN1IyMW9lUGJ6TXhEMVh2MDNzaUtmbTdzVHl1RkNzSHJkUHljQWRRT1pwZVB3bG10bU03Y1lFaTlyenhrY1loM2h3VHFfZ1F3QUVIVjNoMk5tQUhUZmVMQTU0MU1OMHZSVkdYS0ZYSWN0OEZUM0JCTA?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonary hypertension drug developer Gossamer Bio sets May 18 Q1 update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdWVBZjBGOXRPQ1RsWHlZSTc2M2E2U1JXd0NpdHRHbDhibHZyNU04WklrZ3QtRkVFbUM5amoxUVkzZi1MNXZ0ZGJDeFFBQkJhYkJocVFITUw0VV9BRkJaZElWTlZ5Szg2eDVIRUV3aXMxZVFUNWtxb2drNkVtQUxCUmlzb2lPbDZjemNtZGhuQ2xTQTZNOVJXYzBxMFdDOWRZYU9MNjdTbmNwbHpPOWtBU093LXBwek5tT2h4TA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Gossamer Bio (GOSS) Story Is Shifting After The PROSERA Miss And Cash Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxON21NUExmYVZHUVMwRWg4RHd2SEc3UXFnVDFIa3NzRDJRQzBfTkVYdlRSZV9YWFdkam42dWtKbVloS2hBTzhwSFVUMHRyM0FmSWlmd0JiaTF2NWNHVkg4Q19vdEVoRDkzbkVMaDEtRE5CTGZrc0RjRG5wNnp5dHhMYXBGWGUxR1hRQ0xVMUViSmU1cjFvaElmeDNpREJka3VZUVNR?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 Setback", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQdzRGVE9mZl93aDhHOXlpbURfS01KUWRpZTd4ZVZxOEQzaXlUVzBNZGIxWlRhZ0V6OVp0UXlfTGpZTXFQc3pva2tpeE5nZHhBclJNMHVTLTVhTTJHYzhsaDRvTDJ2RENlNWo1ZXVhYkpYMUc2Smpsd3FDQVBjUjRGTTlEWHFvZlJuUzlRMmg5UHJ0bzUxR0tPQUo3RklkTUJEVnk0?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Bullish Analysts Still See Major Upside in Gossamer Bio (GOSS) After PROSERA Setback", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPaDA5R0h1cDljZ0lYY2cwZVE3M0RNVk1xUDZzZEE2QmVoc3lZb0t3a0N0OTcyZnNzRXAxam9ZWXUxYlE4YzNENndMOVhPS08zQllBeTlWZFl5VEVNd3VuTjFad3pYOXlxMURtTVdSVTl4TkJkazYxU05zUGJzc21rV0M0T2F6cDloOExpWXB1Rlc2ZGNGUUUwMG5PUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) Continues Downtrend Despite Impressive Revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOQUtyZFdiZ3pXRVRReFFFSWNlcVFZZnQ3YlRMdWw4dVVfX1pQNzVIRDJDUVdLRkhwM3hQSHRVaWFUTWxDYXMtbGtxanQ1eDh2M3hTUG5jRHRHaDZJNVFMUm02UUdOY2NVajJUbURqRGtCcGN2NnBQOUdVcFdIVHFPNHhOaXVyWGhkZmRJekhCenBwRy1iRU05ZDVreXU0TE5PXzRmTkdUUHA0UQ?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gossamer Bio (GOSS) Quarterly Loss Deepens To US$47 Million Testing Bullish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Gossamer Bio, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNMkVkVjBLcDRYOERnTFUxX1VHa2NOVHNOcVJPV0wtUW5VV3NLV3k5dzBxeUFSSDhyRXVTb0dZZWJESjVFeUR6WEZtUHN6N3NobFkzTE5wWGpSbjRLQk82UkhieEFXUkZvbm1ITjU3RmRCeDNEMl83MEtTVGY2VV91Y3Ewb19kam1STzhKbE4xYWZxWVBZTFU2Q2c2dGQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street Valuations", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOMDh4bUhHX0ZnZlNVUUlTSXNTRFhzYTdWNnJHYXRkLU9CQUhpNXE0TTRfU3Q1NFQxRVhEbnQ5aHREUnlIb1FUQi1wak9tZldibTExS1AtVmdFb1FJend0WG5hdnZiaVpqRHowdkttZVBaZ0ZnMGs2ZzVWTlVsSEVBREpsOTE?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBsQTdCS24zQ3QxdFVlSWtRcGpjb0Nra1RfWFVoTFNEQ0g4cC1kU0hTSFZURTA4VjlLNGhrR19FVUdaTDBCZnktUWxBSXRiYVZWWkNveE52THV1OVdYSlJaTFdqeWw2SzFvRW96Sk1YckRHRVhRZVQyd2VOZjJ2dw?oc=5", "source_name": "Market source", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 65, "sentiment_summary": {"positive": 8, "negative": 17, "neutral": 40, "score": 46, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 73, "events": [{"event": "general", "label": "Market update", "weight": 12.65, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 11.41, "count": 23}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.4, "count": 8}, {"event": "analyst", "label": "Analyst action", "weight": 4.4, "count": 8}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 17}, "market_context": {"has_market_context": true, "latest_close": 0.17, "latest_week": "2026-07-10", "one_week_move": -2.0, "four_week_move": 4.8, "twelve_week_move": -62.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.319892, "market_dynamics_buy_signal": false, "relative_strength": -91.762385, "fair_value_gap": -86.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.9054, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.0% over one week, +4.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Stock Titan", "count": 9}, {"label": "TradingView", "count": 6}, {"label": "ACCESS Newswire", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Business Wire", "count": 3}, {"label": "Quartr", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 23}, {"label": "Market update", "count": 23}, {"label": "Regulatory and legal", "count": 8}, {"label": "Analyst action", "count": 8}, {"label": "Balance sheet", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "46/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "73/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.0% over one week, +4.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B"}], "updated_at": "2026-07-16T18:24:59.634237+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}